Biostate AI is a technology company.
Biostate AI has raised $16.0M across 2 funding rounds.
Biostate AI has raised $16.0M in total across 2 funding rounds.
Biostate AI has raised $16.0M in total across 2 funding rounds.
Biostate AI's investors include Addition, Drive Capital, Matter Venture Partners, Tiger Global Management, Sahin Boydas.
Biostate AI is a biotechnology company developing generative AI models that analyze large-scale omics datasets, particularly RNA sequencing (RNA-seq), to predict health changes, disease progression, and drug responses for personalized medicine.[1][2][3] It serves clinicians, researchers, hospitals, and pharma companies by solving high costs and inaccuracies in diagnostics for conditions like leukemia, coronary artery disease, multiple sclerosis, melanoma, and cancers, while reducing RNA-seq costs by up to 85% through proprietary wetlab technologies like BIRT, PERD, and MARE.[1][2][3] The company has raised $12M (₹99.60 Cr) in funding, established global partnerships including with Mass General Brigham (U.S.), Kindstar Global (China), and an Indian subsidiary Bayosthiti, and maintains a presence in Bengaluru, Houston, and beyond, driving growth in precision health.[1][2][3]
Biostate AI was founded by David Zhang (Co-founder and CEO, former professor and repeat entrepreneur) and Ashwin Gopinath (former professor and repeat entrepreneur), who identified RNA as an underutilized real-time health biomarker that AI could enhance for precision medicine.[2] The idea emerged from their expertise in combining RNA-seq with AI to enable predictive healthcare, leading to proprietary cost-reducing technologies for large-scale data collection.[1][3] Early traction includes major collaborations: a U.S. partnership with Mass General Brigham for melanoma immunotherapy models, a joint venture with China's Kindstar Global (accessing 3,000+ hospitals), and an Indian subsidiary Bayosthiti working with cancer and cardiovascular hospitals.[2] The company has also added Prasad Chintamaneni (ex-Cognizant President, New Mountain Capital advisor) to its board, signaling rapid scaling.[2]
Biostate AI rides the convergence of AI-driven precision medicine and falling genomics costs, timing perfectly with surging demand for predictive healthcare amid aging populations and post-pandemic focus on individualized therapies.[1][2][3] Market forces like expanding RNA-seq adoption (for real-time gene activity snapshots) and global data-sharing collaborations favor it, as does the push for affordable diagnostics in emerging markets like India/China.[1][2] It influences the ecosystem by democratizing omics-AI tools, accelerating drug development, and enabling "90% of humanity to live to 90" through predictive models—positioning as a leader in the $100B+ precision health space.[3]
Biostate AI is poised to dominate AI-biotech integration with its next-gen wetlab-AI stack, likely expanding K-Dense-like agents for broader disease screening and pharma partnerships amid rising longevity tech trends.[3][4] Evolving regulations on AI in healthcare and global data interoperability will shape its path, potentially amplifying influence via more joint ventures and subsidiary growth.[2] As it scales from Bengaluru to Boston, Biostate could redefine precision health, turning RNA snapshots into everyday clinical superpowers—fulfilling its mission to connect samples, data, and decisions for a predictive future.[1][3]
Biostate AI has raised $16.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $12.0M Series A | Addition, Drive Capital, Matter Venture Partners, Tiger Global Management, Sahin Boydas | |
| Jul 1, 2024 | $4.0M Seed | Addition, Drive Capital, Matter Venture Partners, Tiger Global Management, Sahin Boydas |